Business
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023. “We continue to make important progress in advancing our portfolio of drug candidates,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “Phase 2a enabling activities for our lead program in NASH, ALG-055009, are going well and we remain on track to file this important Phase 2a protocol to the US IND in Q4 2023. Additionally, our COVID-19 protease inhibitor, ALG-097558, is now dosing in the clinic in a first in human study and our best-in-class capsid assembly modulator, ALG-000184, continues to generate impressive DNA, RNA, and HBsAg lowering activity as dosing continues in CHB subjects. We look forward to sharing emerging data from these exciting programs at future scientific conferences.” Recent Business Progress Aligos Portfolio of Drug Candidates NASH Program (ALG-055009) Dosing in the Phase 1 first-in-human study is now complete and the database is locked. Data at all dose levels continue to support a favorable risk-benefit profile for ALG-055009Phase 2a enabling activities (e.g., drug manufacturing, non-clinical studies) are ongoing and on track for a Q4 2023 filing of the Phase 2a protocolKey design elements/milestones of the Phase 2a study have been formulated and include: Randomized, double-blind, placebo-controlled trial evaluating dosing for 12 weeksEvaluation of multiple dose levels of ALG-055009 vs. placebo (gelcap formulation)Primary endpoint based on change from baseline at 12 weeks in MRI-PDFFAdditional non-invasive biomarkers commonly evaluated in NASH trials will also be assessedAll sites will be in the USAnticipated top line data: Q4 2024 Stephen Harrison, MD has signed on to be the Phase 2a study’s Principal Investigator COVID-19 (ALG-097558) The first-in-human study (ALG-097558-701) clinical trial application was approved in the UKDosing in Part 1, which is evaluating single ascending oral doses in healthy volunteers, of this multi-part study is ongoingDosing is expected to continue throughout 2023 and early 2024 with topline data anticipated in H1 20...